While certain studies posit that CD10 overexpression is a standalone negative prognostic indicator in cancer prognosis, as supported by findings from Ahem et al. and others (Avery et al., 2000; Ordi et al., 2003; Jung and Kuo, 2005; Ahlem et al., 2015; Gjorgova-Gjeorgjievski et al., 2021), there is contrasting evidence indicating downregulation of CD10 in various cancers, including lung and prostate cancer, as reported by Papandreou et al. (1998), Kristiansen et al. (2002). This evidence concerns the gene MME and prostate cancer.